Compare Boston Scientific Corporation (BSX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Phillips 66 — how do they compare? Boston Scientific Corporation trades at $43.03 (market cap $66.37B), while Phillips 66 trades at $199.3 (market cap $80.77B). The key difference: Phillips 66 is the larger of the two by market cap, and Phillips 66 pays a 2.52% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PSX | |
|---|---|---|
Market Cap | $66.37B | $80.77B |
Sector | Health | Energy |
52-Week High | $108.14 | $201.45 |
52-Week Low | $42.63 | $118.37 |
Enterprise Value | $75.94B | $102.74B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Phillips 66 (PSX) trades at $198.29, up 5.27% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 19.59, P/S of 0.6, and ROE of 14.75%, though revenue declined from $170B in 2022 to $132.38B in 2025. Recent earnings beats and consistent dividends of $1.27 quarterly support investor confidence amid refining margin strength.
Outlook remains positive with analyst consensus at Buy (57%) and $201.50 target, though risks include volatile oil prices, declining revenue trends, and high RSI suggesting overbought conditions. The refining sector benefits from Middle East tensions, but execution on cost control and margin stability will dictate near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
